SEC Form 4 · accession 0001140361-17-040741
ARGOS THERAPEUTICS INC · ARGS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Oct 31, 2017
Accepted (ET)
Nov 2, 2017 · 3:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001105533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Oct 31, 2017 | J | 99,495 | $795.96 | D | 13,142,784 | I | Pharmstandard International S.A. is a wholly owned subsidiary of Joint Stock Company Pharmstandard. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares transferred as partial payment pursuant to a service agreement with IBK Company Limited dated 16 September 2016.
- F2Pharmstandard International S.A. is a wholly owned subsidiary of Joint Stock Company Pharmstandard. As the parent entity, Joint Stock Company Pharmstandard has voting power over the shares of the Issuer held by Pharmstandard International S.A.